Menveo(TM) (MenACWY-CRM) vaccine to demonstrate an excellent immune response in infants
- Details
- Category: Novartis
New clinical data for the Novartis development vaccine Menveo(TM) [2] (MenACWY-CRM) show an excellent and broad immune response in infants as young as six months of age against four common serogroups (or types) of meningococcal meningitis, a potentially fatal bacterial disease involving inflammation of membranes around the brain and spinal cord.
Pfizer to Acquire Coley Pharmaceutical Group
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) announced today it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc. (NASDAQ: COLY), a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.
Abbott Partners With Operation Smile to Support 40 Medical Missions in 25 Countries
- Details
- Category: Abbott
Abbott (NYSE: ABT) is supporting Operation Smile's global initiative to help bring smiles to kids with facial deformities by providing treatment to an estimated 5,000 children in need of surgeries. The initiative, which is part of Operation Smile's 25th anniversary celebration - World Journey of Smiles - takes place this month and consists of 40 medical missions across 25 countries. Abbott has donated 1,700 bottles of its anesthesia product, valued at almost $500,000, for the surgeries.
Award recognises and rewards journalism that extends public awareness and understanding of COPD
- Details
- Category: Boehringer Ingelheim
The independent judging panel of the Eloquium Award has today named three journalists as winners of the 2007 competition for excellence in reporting on chronic obstructive pulmonary disease (COPD) the fastest growing cause of death in the world's most advanced economies. Currently, 600 million people live with COPD which is projected to become the worldâs third-leading cause of death by 2020.[1,2]
Roche signs licensing and settlement agreements for Hepatitis C immunodiagnostics
- Details
- Category: Roche
Roche announced licensing and settlement agreements with Ortho-Clinical Diagnostics, Inc. and Novartis Vaccines & Diagnostics in the field of Hepatitis C Virus (HCV) Diagnostics. Under the terms of the licensing agreement Ortho-Clinical Diagnostics, Inc. and Novartis Vaccines & Diagnostics granted Roche Diagnostics a worldwide royalty-bearing license under their broad patent portfolio for Hepatitis C Virus (HCV) in the field of immunodiagnostics.
Novo Nordisk celebrates first ever UN-observed World Diabetes Day
- Details
- Category: Novo Nordisk
14 November is World Diabetes Day (WDD). This year is the first time that WDD is officially recognised by the United Nations. Novo Nordisk is celebrating the day with activities all over the world, from the UN building in New York to the pyramids of Egypt.
Novel agent for treatment of Parkinson's disease in clinical development
- Details
- Category: Lundbeck
Lundbeck has initiated phase I clinical trials with the pharmaceutical candidate Lu AA47070 to investigate safety, tolerability and the pharmacokinetic profile of the compound in humans. Lu AA47070 is a novel adenosine receptor antagonist that has been shown to be efficacious in a number of animal models for neurological diseases including models of Parkinson's disease.
More Pharma News ...
- New Phase III Trial Results for Rivaroxaban
- Novo Nordisk launches Changing Diabetes Barometer
- Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function
- Bayer Temporarily Suspends Global Trasylol® Marketing
- Novo Nordisk celebrates 75-year commitment to diabetes research
- Taisho and Pfizer Sign a Letter of Intent for Taishoâs Schizophrenia Drug Candidate
- Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients